IL6 and inflammatory bowel disease: Study results to date, particularly the effectiveness of olamkicept evaluated in two phase 2 trials in patients with IBD [71,72], are promising, but the benefits of IL-6 inhibitors need to be verified in larger studies to warrant their potential approval in this indication.